Brain cancer-associated stroke represents a complex interplay of oncological and cerebrovascular factors, distinct from conventional stroke mechanisms. Tumor-induced hypercoagulability, inflammation, and vascular disruption converge to create a unique clinical challenge that demands precision in diagnosis and management. This review synthesizes current evidence on the pathophysiological mechanisms, diagnostic innovations, and therapeutic strategies for brain cancer-related stroke while introducing two transformative frameworks designed to improve patient outcomes. We propose the Tumoral Bleeding Classification System (TBCS), a novel phenotypic framework categorizing tumoral bleeding into intratumoral and peritumoral subtypes, with further subdivisions to guide clinical decision-making. By linking these classifications to diagnostic biomarkers, such as D-dimer, and advanced imaging techniques, such as magnetic resonance imaging, the TBCS may enhance risk stratification and therapeutic targeting. Building on these insights, the CanStroke protocol offers an integrated, multidisciplinary, evidence-based management strategy tailored for brain cancer patients at risk of stroke. This protocol bridges oncology, neurology, and vascular medicine to address key challenges, including early recognition of stroke risk, individualized treatment plans, and mitigation of complications. Central to this approach is the integration of molecular diagnostics and pharmacogenomic data to optimize treatment pathways, aligning with precision medicine principles. This article highlights the critical need for diagnostic-therapeutic frameworks in brain cancer-related stroke, underscoring the value of the TBCS and CanStroke protocol in transforming care. By linking diagnostic biomarkers, imaging techniques, and therapeutic strategies, these innovations pave the way for improved survival, reduced morbidity, and enhanced quality of life in this vulnerable population.
FeiginVL, StarkBA, JohnsonCO, . Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820.
2.
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768.
3.
CestariDM, WeineDM, PanageasKS, SegalAZ, DeAngelisLM.Stroke in patients with cancer: incidence and etiology. Neurology. 2004;62(11):2025–2030. https://doi.org/10.1212/01.wnl.0000129912.56486.2b
4.
KreislTN, ToothakerT, KarimiS, DeAngelisLM.Ischemic stroke in patients with primary brain tumors. Neurology. 2008;70(24):2314–2320. https://doi.org/10.1212/01.wnl.0000314648.82924.6f
5.
NaviBB, ReinerAS, KamelH, . Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133(8):781–789. https://doi.org/10.1182/blood-2018-06-860874
6.
WeiYC, ChenKF, WuCL, . Stroke rate increases around the time of cancer diagnosis. Front Neurol. 2019;10:579. https://doi.org/10.3389/fneur.2019.00579
7.
ConenD, WongJA, SandhuRK, . Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol. 2016;1(4):389–396. https://doi.org/10.1001/jamacardio.2016.0280
LindvigK, MøllerH, MosbechJ, JensenOM.The pattern of cancer in a large cohort of stroke patients. Int J Epidemiol. 1990;19(3):498–504. https://doi.org/10.1093/ije/19.3.498
10.
ChenCW, ChengTJ, HoCH, . Increased risk of brain cancer incidence in stroke patients: a clinical case series, population-based and longitudinal follow-up study. Oncotarget. 2017;8(65):108989–108999. https://doi.org/10.18632/oncotarget.22480
11.
VerhoevenJI, FanB, BroedersMJM, . Association of stroke at young age with new cancer in the years after stroke among patients in the Netherlands. JAMA Netw Open. 2023;6(3):e235002. https://doi.org/10.1001/jamanetworkopen.2023.5002
12.
HatzitoliosA, SavopoulosC, NtaiosG, . Stroke and conditions that mimic it: a protocol secures a safe early recognition. Hippokratia. 2008;12(2):98–102.
RichardSA, YeY, LiH, MaL, YouC.Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: a case report and literature review. Neurol Int. 2018;10(1):7558. https://doi.org/10.4081/ni.2018.7558
HamedM, SchäferN, BodeC, . Preoperative metastatic brain tumor-associated intracerebral hemorrhage is associated with dismal prognosis. Front Oncol. 2021;11:699860. https://doi.org/10.3389/fonc.2021.699860
18.
ShiY, KangX, GeY, . The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis. BMC Neurol. 2024;24(1):202. https://doi.org/10.1186/s12883-024-03703-2
19.
BosnjakR, DerhamC, PopovićM, RavnikJ.Spontaneous intracranial meningioma bleeding: clinicopathological features and outcome. J Neurosurg. 2005;103(3):473–484. https://doi.org/10.3171/jns.2005.103.3.0473
20.
LeeMJ, ChungJW, AhnMJ, . Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study. J Stroke. 2017;19(1):77–87. https://doi.org/10.5853/jos.2016.00570
21.
ItoS, KikuchiK, UedaA, . Changes in serial D-dimer levels predict the prognoses of Trousseau’s syndrome patients. Front Neurol. 2018;9:528. https://doi.org/10.3389/fneur.2018.00528
22.
NamKW, KimCK, KimTJ, . D-dimer as a predictor of early neurologic deterioration in cryptogenic stroke with active cancer. Eur J Neurol. 2017;24(1):205–211. https://doi.org/10.1111/ene.13184
23.
KimSJ, ParkJH, LeeM-J, ParkYG, AhnMJ, BangOY.Clues to occult cancer in patients with ischemic stroke. PLoS One. 2012;7(9):e44959. https://doi.org/10.1371/journal.pone.0044959
24.
Erritzøe-JervildM, WenstrupJ, HougaardBH, KruuseC.Diagnosing cancer-associated ischemic stroke: a systematic review of hematological biomarkers. Int J Stroke. 2024;19(6):622–634. https://doi.org/10.1177/17474930241227385
25.
BangOY, ChungJW, ChoYH, . Circulating DNAs, a marker of neutrophil extracellular traposis and cancer-related stroke: the OASIS-Cancer study. Stroke. 2019;50(10):2944–2947. https://doi.org/10.1161/strokeaha.119.026373
26.
NaviBB, MathiasR, ShermanCP, . Cancer-related ischemic stroke has a distinct blood mRNA expression profile. Stroke. 2019;50(11):3259–3264. https://doi.org/10.1161/strokeaha.119.026143
27.
BangOY, ChungJW, LeeMJ, . Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASIS-CANCER study. PLoS One. 2016;11(7):e0159170. https://doi.org/10.1371/journal.pone.0159170
28.
IzumiT, NanauraH, IguchiN, OzakiM, SugieK.Low serum eicosapentaenoic acid levels in cryptogenic stroke with active cancer. J Stroke Cerebrovasc Dis. 2020;29(8):104892. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104892
29.
YoshimotoT, ToyodaK, YoshimuraS, . Outcomes in ischemic and hemorrhagic stroke patients with cancer: the Japan Stroke Data Bank. J Neurol Sci. 2024;466:123234. https://doi.org/10.1016/j.jns.2024.123234
30.
NaviBB, IadecolaC.Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol. 2018;83(5):873–883. https://doi.org/10.1002/ana.25227
31.
ShengB, FongMK, ChuYP, . Stroke and cancer: misfortunes never come singularly. Int J Stroke. 2013;8(6):E30. https://doi.org/10.1111/ijs.12071
32.
ZhangF, WangK, DuP, . Risk of stroke in cancer survivors: a meta-analysis of population-based cohort studies. Neurology. 2021;96(4):e513–e526. https://doi.org/10.1212/wnl.0000000000011264
33.
TurnerM, MurchieP, DerbyS, . Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis. J Cancer Surviv. 2022;16(6):1414–1448. https://doi.org/10.1007/s11764-021-01122-7
34.
LunR, RoyDC, HaoY, . Incidence of stroke in the first year after diagnosis of cancer—a systematic review and meta-analysis. Front Neurol. 2022;13:966190. https://doi.org/10.3389/fneur.2022.966190
35.
ZöllerB, JiJ, SundquistJ, SundquistK.Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(12):1875–1883. https://doi.org/10.1016/j.ejca.2012.01.005
36.
SunMY, BhaskarSMM.When two Maladies meet: disease burden and pathophysiology of stroke in cancer. Int J Mol Sci. 2022;23(24):15769. https://doi.org/10.3390/ijms232415769
37.
FangJ, ShawKM, GeorgeMG.Prevalence of stroke—United States, 2006–2010 (Reprinted from MMWR, Vol 61, Pg 379, 2012). JAMA. 2012;308:228–230.
38.
MenounosS, ShenH, TipirneniS, BhaskarSMM.Decoding the nexus: cellular and molecular mechanisms linking stroke and neurotoxic microenvironments in brain cancer patients. Biomolecules. 2024;14(12):1507. https://doi.org/10.3390/biom14121507
39.
NaviBB, HowardG, HowardVJ, . New diagnosis of cancer and the risk of subsequent cerebrovascular events. Neurology. 2018;90(23):e2025–e2033. https://doi.org/10.1212/wnl.0000000000005636
40.
NaviBB, HowardG, HowardVJ, . The risk of arterial thromboembolic events after cancer diagnosis. Res Pract Thromb Haemost. 2019;3(4):639–651. https://doi.org/10.1002/rth2.12223
41.
RogersLR.Cerebrovascular complications in cancer patients. Neurol Clin. 2003;21(1):167–192. https://doi.org/10.1016/s0733-8619(02)00066-x
42.
GrausF, RogersLR, PosnerJB.Cerebrovascular complications in patients with cancer. Medicine (Baltimore). 1985;64(1):16–35. https://doi.org/10.1097/00005792-198501000-00002
43.
VelanderAJ, DeAngelisLM, NaviBB.Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep. 2012;14(4):373–381. https://doi.org/10.1007/s11883-012-0250-3
44.
OrphanosG, ArdavanisA.Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clin Exp Metastasis. 2010;27(1):19–23. https://doi.org/10.1007/s10585-009-9298-z
HermanC, KupskyWJ, RogersL, DumanR, MooreP.Leptomeningeal dissemination of malignant glioma simulating cerebral vasculitis. Case report with angiographic and pathological studies. Stroke. 1995;26(12):2366–2370. https://doi.org/10.1161/01.str.26.12.2366
47.
KondziolkaD, BernsteinM, ReschL, . Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg. 1987;67(6):852–857. https://doi.org/10.3171/jns.1987.67.6.0852
48.
KimDG, ParkCK, PaekSH, . Meningioma manifesting intracerebral haemorrhage: a possible mechanism of haemorrhage. Acta Neurochir (Wien). 2000;142(2):165–168. https://doi.org/10.1007/s007010050019
49.
WangHC, WangBD, ChenMS, . An underlying pathological mechanism of meningiomas with intratumoral hemorrhage: undifferentiated microvessels. World Neurosurg. 2016;94:319–327. https://doi.org/10.1016/j.wneu.2016.07.042
50.
ZhouJ-h, WangC, YangD, . Clinical features and treatment of apoplectic intratumoral hemorrhage of glioma. BMC Neurol. 2024;24(1):254. https://doi.org/10.1186/s12883-024-03753-6
51.
SalmaggiA, ErbettaA, SilvaniA, MadernaE, PolloB.Intracerebral haemorrhage in primary and metastatic brain tumours. Neurol Sci. 2008;29 Suppl 2:S264–S265. https://doi.org/10.1007/s10072-008-0958-6
52.
BaruaKK, TamakiN, EharaK, NagashimaT, SuzukiH.Spontaneous peritumoral haemorrhage associated with sinus confluence meningioma: case report. Surg Neurol. 2000;54(3):254–259. https://doi.org/10.1016/s0090-3019(00)00299-8
53.
GonY, OkazakiS, TerasakiY, . Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280–287. https://doi.org/10.1002/acn3.291
54.
NaviBB, KasnerSE, ElkindMSV, . Cancer and embolic stroke of undetermined source. Stroke. 2021;52(3):1121–1130. https://doi.org/10.1161/strokeaha.120.032002
55.
Sealy-JeffersonS, CoteML, ChlebowskiRT, RexrodeKM, SimonMS.Post-stroke cancer risk among postmenopausal women: the women’s health initiative. Womens Health Issues. 2018;28(1):29–34. https://doi.org/10.1016/j.whi.2017.10.012
56.
SchwarzbachCJ, SchaeferA, EbertA, . Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke. 2012;43(11):3029–3034. https://doi.org/10.1161/strokeaha.112.658625
57.
CaineGJ, StonelakePS, LipGY, KehoeST.The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465–473. https://doi.org/10.1038/sj.neo.7900263
58.
FalangaA, Panova-NoevaM, RussoL.Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49–60. https://doi.org/10.1016/j.beha.2008.12.009
59.
DahlbäckB, VilloutreixBO.Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol. 2005;25(7):1311–1320. https://doi.org/10.1161/01.Atv.0000168421.13467.82.
60.
DittmanWA, MajerusPW.Structure and function of thrombomodulin: a natural anticoagulant. Blood. 1990;75(2):329–336.
61.
D’AstiE, FangY, RakJ.Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J. 2014;5(4):e0030. https://doi.org/10.5041/rmmj.10164
62.
RongY, PostDE, PieperRO, DurdenDL, Van MeirEG, BratDJ.PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005;65(4):1406–1413. https://doi.org/10.1158/0008-5472.Can-04-3376
63.
MonteiroRQ, LimaLG, GonçalvesNP, . Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncol Lett. 2016;12(1):315–322. https://doi.org/10.3892/ol.2016.4593
64.
KneihslM, EnzingerC, WünschG, . Poor short-term outcome in patients with ischaemic stroke and active cancer. J Neurol. 2016;263(1):150–156. https://doi.org/10.1007/s00415-015-7954-6
65.
CuttingS, WettengelM, ConnersJJ, OuyangB, BuslK.Three-month outcomes are poor in stroke patients with cancer despite acute stroke treatment. J Stroke Cerebrovasc Dis. 2017;26(4):809–815. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.021
66.
YooJ, NamHS, KimYD, LeeHS, HeoJH.Short-term outcome of ischemic stroke patients with systemic malignancy. Stroke. 2019;50(2):507–511. https://doi.org/10.1161/strokeaha.118.023044
67.
KhoranaAA, FrancisCW, CulakovaE, Lobo SamperF.Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. https://doi.org/10.1002/cncr.23062
68.
LevitanN, DowlatiA, RemickSC, . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–291. https://doi.org/10.1097/00005792-199909000-00001
69.
KhoranaAA, FrancisCW, CulakovaE, FisherRI, KudererNM, LymanGH.Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–490. https://doi.org/10.1200/jco.2005.03.8877
70.
SallahS, WanJY, NguyenNP.Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575–579.
OhataH, UdaT, SasakiT, . Glioblastoma presented with acute ischemic stroke: a case report and literature review. Interdiscip Neurosurg. 2021;24:101099. https://doi.org/10.1016/j.inat.2021.101099
73.
DropulicLK, LedermanHM.Overview of infections in the immunocompromised host. Microbiol Spectr. 2016;4(4). https://doi.org/10.1128/microbiolspec.DMIH2-0026-2016
74.
ElkindMSV, BoehmeAK, SmithCJ, MeiselA, BuckwalterMS.Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020;51(10):3156–3168. https://doi.org/10.1161/strokeaha.120.030429
RyanD, SugitaM, LippE, El HusseiniN, PetersK.Strokes in patients with primary brain tumors after radiation therapy: a retrospective cohort study (P3-13.006). Neurology. 2023;100(17_supplement_2):3964. https://doi.org/10.1212/WNL.0000000000203644
77.
KitanoT, SasakiT, GonY, . The effect of chemotherapy on stroke risk in cancer patients. Thromb Haemost. 2020;120(4):714–723. https://doi.org/10.1055/s-0040-1708484
78.
HuangR, ZhouY, HuS, RenG, CuiF, ZhouPK.Radiotherapy exposure in cancer patients and subsequent risk of stroke: a systematic review and meta-analysis. Front Neurol. 2019;10:233. https://doi.org/10.3389/fneur.2019.00233
79.
ZuoPY, ChenXL, LiuYW, XiaoCL, LiuCY.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One. 2014;9(7):e102484. https://doi.org/10.1371/journal.pone.0102484
80.
DrobniZD, AlviRM, TaronJ, . Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–2311. https://doi.org/10.1161/circulationaha.120.049981
81.
ChiangCH, ChiangCH, MaKS, . The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol. 2022;52(12):1389–1398. https://doi.org/10.1093/jjco/hyac150
82.
TrianaAM, SaramäkiJ, GlereanE, HaywardNMEA.Neuroscience meets behavior: a systematic literature review on magnetic resonance imaging of the brain combined with real-world digital phenotyping. Hum Brain Mapp. 2024;45(4):e26620. https://doi.org/10.1002/hbm.26620
83.
BirenbaumD, BancroftLW, FelsbergGJ.Imaging in acute stroke. West J Emerg Med. 2011;12(1):67–76.
84.
LatchawRE, AlbertsMJ, LevMH, . Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke. 2009;40(11):3646–3678. https://doi.org/10.1161/STROKEAHA.108.192616
85.
MartucciM, RussoR, SchimpernaF, . Magnetic resonance imaging of primary adult brain tumors: state of the art and future perspectives. Biomedicines. 2023;11(2):364. https://doi.org/10.3390/biomedicines11020364
86.
SmirniotopoulosJG, MurphyFM, RushingEJ, ReesJH, SchroederJW.Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27(2):525–551. https://doi.org/10.1148/rg.272065155
87.
HuLS, Hawkins-DaarudA, WangL, LiJ, SwansonKR.Imaging of intratumoral heterogeneity in high-grade glioma. Cancer Lett. 2020;477:97–106. https://doi.org/10.1016/j.canlet.2020.02.025
88.
NeuweltEA.Mechanisms of disease: the blood-brain barrier. Neurosurgery2004;54(1):131–140; discussion 141–132. https://doi.org/10.1227/01.neu.0000097715.11966.8e
ManglaR, KolarB, AlmastJ, EkholmSE.Border zone infarcts: pathophysiologic and imaging characteristics. Radiographics. 2011;31(5):1201–1214. https://doi.org/10.1148/rg.315105014
91.
FinelliPF, NouhA.Three-territory DWI acute infarcts: diagnostic value in cancer-associated hypercoagulation stroke (Trousseau syndrome). AJNR Am J Neuroradiol. 2016;37(11):2033–2036. https://doi.org/10.3174/ajnr.A4846
92.
LieuAS, HwangSL, HowngSL, ChaiCY.Brain tumors with hemorrhage. J Formos Med Assoc. 1999;98(5):365–367.
93.
DemeestereJ, WoutersA, ChristensenS, . Review of perfusion imaging in acute ischemic stroke: from time to tissue. Stroke. 2020;51(3):1017–1024. https://doi.org/10.1161/STROKEAHA.119.028337
94.
JainR.Perfusion CT imaging of brain tumors: an overview. AJNR Am J Neuroradiol. 2011;32(9):1570–1577. https://doi.org/10.3174/ajnr.A2263
95.
FranceschiAM, MoschosSJ, AndersCK, . Use of susceptibility-weighted imaging (SWI) in the detection of brain hemorrhagic metastases from breast cancer and melanoma. J Comput Assist Tomogr. 2016;40(5):803–805. https://doi.org/10.1097/rct.0000000000000420
Bauer-NilsenK, TrifilettiDM, ChatrathA, . Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases. J Neurooncol. 2018;140(1):83–88. https://doi.org/10.1007/s11060-018-2933-2
98.
LiXL, ZhouFM, ShangguanSQ, . Application of computed tomography for differential diagnosis of glioma stoke and simple cerebral hemorrhage. Asian Pac J Cancer Prev. 2014;15(8):3425–3428. https://doi.org/10.7314/apjcp.2014.15.8.3425
99.
AyubchaC, AmanullahA, PatelKH, . Stroke and molecular imaging: a focus on FDG-PET. Am J Nucl Med Mol Imaging. 2023;13(2):51–63.
100.
RomingerA, SaamT, WolpersS, . 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50(10):1611–1620. https://doi.org/10.2967/jnumed.109.065151
101.
LangD, WahlG, PoierN, . Impact of PET/CT for assessing response to immunotherapy—a clinical perspective. J Clin Med. 2020;9(11):3483. https://doi.org/10.3390/jcm9113483
102.
SarkarS, GhoshS, GhoshSK, CollierA.Role of transcranial Doppler ultrasonography in stroke. Postgrad Med J. 2007;83(985):683–689. https://doi.org/10.1136/pgmj.2007.058602
103.
BankoleNDA, DujardinP-A, BalaF, . Transcranial Doppler ultrasound for the diagnosis of large vessel occlusion in patients with acute ischemic stroke: a systematic review. Clin Neurol Neurosurg. 2024;245:108506. https://doi.org/10.1016/j.clineuro.2024.108506
MoawadAW, FuentesDT, ElBananMG, . Artificial intelligence in diagnostic radiology: where do we stand, challenges, and opportunities. J Comput Assist Tomogr. 2022;46(1):78–90. https://doi.org/10.1097/rct.0000000000001247
CochoD, GendreJ, BoltesA, . Predictors of occult cancer in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2015;24(6):1324–1328. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.02.006
108.
SelvikHA, BjerkreimAT, ThomassenL, Waje-AndreassenU, NaessH, KvistadCE.When to screen ischaemic stroke patients for cancer. Cerebrovasc Dis. 2018;45(1–2):42–47. https://doi.org/10.1159/000484668
109.
XieW, HsuS, LinY, . Malignancy-associated ischemic stroke: implications for diagnostic and therapeutic workup. CNS Neurosci Ther. 2024;30(3):e14619. https://doi.org/10.1111/cns.14619
110.
LeeEJ, NahHW, KwonJY, KangDW, KwonSU, KimJS.Ischemic stroke in patients with cancer: is it different from usual strokes? Int J Stroke. 2014;9(4):406–412. https://doi.org/10.1111/ijs.12124
111.
TripodiA.D-dimer testing in laboratory practice. Clin Chem. 2011;57(9):1256–1262. https://doi.org/10.1373/clinchem.2011.166249
GuoYJ, ChangMH, ChenPL, LeeYS, ChangYC, LiaoYC.Predictive value of plasma (D)-dimer levels for cancer-related stroke: a 3-year retrospective study. J Stroke Cerebrovasc Dis. 2014;23(4):e249–254. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.022
114.
SeystahlK, GramatzkiD, WannerM, . A risk model for prediction of diagnosis of cancer after ischemic stroke. Sci Rep. 2023;13(1):111. https://doi.org/10.1038/s41598-022-26790-y
115.
KarlińskaAG, GromadzkaG, KarlińskiMA, CzłonkowskaA.The activity of malignancy may determine stroke pattern in cancer patients. J Stroke Cerebrovasc Dis. 2015;24(4):778–783. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.003
116.
SimanekR, VormittagR, AyC, . High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114–120. https://doi.org/10.1111/j.1538-7836.2009.03680.x
117.
BangOY, ChungJW, LeeMJ, . Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms. J Stroke. 2020;22(1):1–10. https://doi.org/10.5853/jos.2019.02278
118.
GruysE, ToussaintMJ, NiewoldTA, KoopmansSJ.Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005;6(11):1045–1056. https://doi.org/10.1631/jzus.2005.B1045
119.
ThålinC, DemersM, BlomgrenB, . NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res. 2016;139:56–64. https://doi.org/10.1016/j.thromres.2016.01.009
120.
AzradM, TurgeonC, Demark-WahnefriedW.Current evidence linking polyunsaturated fatty acids with cancer risk and progression. Front Oncol. 2013;3:224. https://doi.org/10.3389/fonc.2013.00224
121.
SimanekR, VormittagR, HasslerM, . Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9(2):89–95.
122.
HorstedF, WestJ, GraingeMJ.Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. https://doi.org/10.1371/journal.pmed.1001275
123.
JoJT, SchiffD, PerryJR.Thrombosis in brain tumors. In: Seminars in Thrombosis and Hemostasis. New York: Thieme Medical Publishers; 2014:325–331.
KearonC, AklEA, OrnelasJ, . Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. https://doi.org/10.1016/j.chest.2015.11.026
126.
LymanGH, BohlkeK, KhoranaAA, . Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015;33(6):654–656. https://doi.org/10.1200/jco.2014.59.7351
127.
MandalàM, LabiancaR.Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res. 2010;125 Suppl 2:S117–S119. https://doi.org/10.1016/s0049-3848(10)70028-1
FargeD, FrereC, ConnorsJM, . 2022 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. https://doi.org/10.1016/s1470-2045(22)00160-7
130.
HsuJY, LiuAB.Anticoagulants for cancer-associated ischemic stroke. Ci Ji Yi Xue Za Zhi. 2019;31(3):144–148. https://doi.org/10.4103/tcmj.tcmj_55_19
131.
KawanoH, HondaY, AmanoT, . Subcutaneous heparin therapy for patients with cancer-associated stroke. J Stroke Cerebrovasc Dis. 2019;28(2):399–404. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.10.012
132.
EscobarA, SalemAM, DicksonK, . Anticoagulation and bleeding in the cancer patient. Support Care Cancer. 2022;30(10):8547–8557. https://doi.org/10.1007/s00520-022-07136-w
133.
VarkiA.Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723–1729. https://doi.org/10.1182/blood-2006-10-053736
134.
LeeAY, LevineMN, BakerRI, . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153. https://doi.org/10.1056/NEJMoa025313
135.
HullRD, PineoGF, BrantRF, . Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072. https://doi.org/10.1016/j.amjmed.2006.02.022
136.
MeyerG, MarjanovicZ, ValckeJ, . Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735. https://doi.org/10.1001/archinte.162.15.1729
137.
HuoH, ShenS, YangY, . The risk of intracranial hemorrhage in glioma patients receiving anticoagulant treatment for venous thromboembolism: a Bayesian network meta-analysis. J Thromb Thrombolysis. 2023;56(2):333–341. https://doi.org/10.1007/s11239-023-02851-5
138.
MantiaC, UhlmannEJ, PuligandlaM, WeberGM, NeubergD, ZwickerJI.Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017;129(25):3379–3385. https://doi.org/10.1182/blood-2017-02-767285
139.
DonatoJ, CampigottoF, UhlmannEJ, . Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126(4):494–499. https://doi.org/10.1182/blood-2015-02-626788
140.
AlvaradoG, NoorR, BassettR, . Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012;22(4):310–315. https://doi.org/10.1097/CMR.0b013e328353efd8
141.
ZwickerJI, Karp LeafR and CarrierM.A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016;14(9):1736–1740. https://doi.org/10.1111/jth.13387
142.
CarneyBJ, UhlmannEJ, PuligandlaM, . Anticoagulation after intracranial hemorrhage in brain tumors: risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost. 2020;4(5):860–865. https://doi.org/10.1002/rth2.12377
143.
KhoranaAA, McCraeKR, MilentijevicD, . Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost. 2017;1(1):14–22. https://doi.org/10.1002/rth2.12002
144.
NaviBB, MarshallRS, BobrowD, . Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol. 2018;75(3):379–381. https://doi.org/10.1001/jamaneurol.2017.4211
145.
YoungAM, MarshallA, ThirlwallJ, . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. https://doi.org/10.1200/jco.2018.78.8034
146.
RaskobGE, van EsN, VerhammeP, . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. https://doi.org/10.1056/NEJMoa1711948
147.
McBaneRD, WysokinskiWE2nd, Le-RademacherJG, . Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421. https://doi.org/10.1111/jth.14662
148.
AgnelliG, MuñozA, FrancoL, . Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796–807. https://doi.org/10.1055/s-0041-1735194
149.
MoikF, PoschF, ZielinskiC, PabingerI, AyC.Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4(4):550–561. https://doi.org/10.1002/rth2.12359
150.
LeaderA, HamulyákEN, CarneyBJ, . Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv. 2020;4(24):6291–6297. https://doi.org/10.1182/bloodadvances.2020003238
151.
KirkilesisGI, KakkosSK, TsolakisIA.Editor’s Choice—A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg. 2019;57(5):685–701. https://doi.org/10.1016/j.ejvs.2018.11.004
152.
RoseAJ, SharmanJP, OzonoffA, HenaultLE, HylekEM.Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22(7):997–1002. https://doi.org/10.1007/s11606-007-0228-y
153.
TiiliP, LeventisI, KinnunenJ, . Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation. Ann Med. 2021;53(1):1613–1620. https://doi.org/10.1080/07853890.2021.1968031
154.
O’ConnellC, EscalanteCP, GoldhaberSZ, . Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist. 2021;26(1):e8–e16. https://doi.org/10.1002/onco.13584
155.
Del GiovaneC, BoncoraglioGB, BertùL, BanziR, TramacereI.Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Neurol. 2021;21(1):319. https://doi.org/10.1186/s12883-021-02341-2
ParkH, KimJ, HaJ, . Histological features of intracranial thrombi in stroke patients with cancer. Ann Neurol. 2019;86(1):143–149. https://doi.org/10.1002/ana.25495
158.
PipekL, NascimentoR, SilvaGD.Secondary prevention for ischemic stroke in patients with cancer: a systematic review and network meta-analysis (P3-5.024). Neurology. 2024;102(7 Supplement 1):5688.
159.
Martinez-MajanderN, NtaiosG, LiuYY, . Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. Eur J Neurol. 2020;27(5):841–848.
160.
MaS, PatellR, MillerE, . Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors. J Thromb Haemost. 2023;21(5):1148–1155. https://doi.org/10.1016/j.jtha.2023.01.031
161.
MillerEJ, PatellR, UhlmannEJ, . Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. Blood Adv. 2022;6(5):1559–1565. https://doi.org/10.1182/bloodadvances.2021006470
162.
XiaY, HuY, TangL.Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances. Pharmaceuticals. 16(6):866. https://doi.org/10.3390/ph16060866
163.
ParkK, BavryAA.Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25–32. https://doi.org/10.2147/vhrm.S54159
164.
UngprasertP, MattesonEL, ThongprayoonC.Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hemorrhagic stroke: a systematic review and meta-analysis of observational studies. Stroke. 2016;47(2):356–364. https://doi.org/10.1161/strokeaha.115.011678
ErenOT, ArmağanR, TalmaçMA.Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Musculoskelet Res Basic Sci. 2016:683–693.
167.
SolerMF, AbaurreaA, AzcoagaP, AraujoAM, CaffarelMM.New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer. 2023;11(11):e007530. https://doi.org/10.1136/jitc-2023-007530
168.
WangM, ChenS, HeX, YuanY, WeiX.Targeting inflammation as cancer therapy. J Hematol Oncol. 2024;17(1):13. https://doi.org/10.1186/s13045-024-01528-7
169.
JiangW, J-WHu, X-RHe, JinWL, HeXY.Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241. https://doi.org/10.1186/s13046-021-02041-2
170.
LiuC, ChenH, HuB, ShiJ, ChenY, HuangK.New insights into the therapeutic potentials of statins in cancer. Front Pharmacol. 2023;14:1188926. https://doi.org/10.3389/fphar.2023.1188926
171.
TramacereI, BoncoraglioGB, BanziR, . Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med. 2019;17(1):67. https://doi.org/10.1186/s12916-019-1298-5
172.
BrahmCG, van LindeME, EntingRH, . The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review. Cancers (Basel). 2020;12(3):586. https://doi.org/10.3390/cancers12030586
Di NisioM, PorrecaE, CandeloroM, ValerianiE, Di NisioM.Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12(12):CD008500. https://doi.org/10.1002/14651858.CD008500.pub4
175.
CarrierM, Abou-NassarK, MallickR, . Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711–719. https://doi.org/10.1056/NEJMoa1814468
176.
KhoranaAA, SoffGA, KakkarAK, . Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. https://doi.org/10.1056/NEJMoa1814630
177.
KatzJM, SegalAZ.Incidence and etiology of cerebrovascular disease in patients with malignancy. Curr Atheroscler Rep. 2005;7(4):280–288. https://doi.org/10.1007/s11883-005-0020-6
178.
GrisoldW, OberndorferS, StruhalW.Stroke and cancer: a review. Acta Neurol Scand. 2009;119:1–16. https://doi.org/10.1111/j.1600-0404.2008.01059.x
HuangJ-T, MaoY-Q, HanB, . Calorie restriction conferred improvement effect on long-term rehabilitation of ischemic stroke via gut microbiota. Pharmacol Res. 2021;170:105726. https://doi.org/10.1016/j.phrs.2021.105726
184.
JinK, BrennanPM, PoonMTC, SudlowCLM, FigueroaJD.Raised cardiovascular disease mortality after central nervous system tumor diagnosis: analysis of 171,926 patients from UK and USA. Neurooncol Adv. 2021;3(1):vdab136. https://doi.org/10.1093/noajnl/vdab136
185.
ShortNJ, ConnorsJM.New oral anticoagulants and the cancer patient. Oncologist. 2014;19(1):82–93. https://doi.org/10.1634/theoncologist.2013-0239
186.
SelvikHA, ThomassenL, LogalloN, NæssH.Prior cancer in patients with ischemic stroke: the Bergen NORSTROKE study. J Stroke Cerebrovasc Dis. 2014;23(5):919–925. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.041
187.
MulderFI, Horváth-PuhóE, van EsN, . Arterial thromboembolism in cancer patients: a Danish population-based cohort study. JACC CardioOncol. 2021;3(2):205–218. https://doi.org/10.1016/j.jaccao.2021.02.007
188.
PanaTA, MohamedMO, MamasMA, MyintPK.Prognosis of acute ischaemic stroke patients with cancer: a national inpatient sample study. Cancers (Basel). 2021;13(9):2193. https://doi.org/10.3390/cancers13092193
189.
KikunoM, UenoY, TakekawaH, . Distinction in prevalence of atherosclerotic embolic sources in cryptogenic stroke with cancer status. J Am Heart Assoc. 2021;10(21):e021375. https://doi.org/10.1161/jaha.120.021375
190.
LunaLP, SherbafFG, SairHI, MukherjeeD, OliveiraIB, KöhlerCA.Can preoperative mapping with functional MRI reduce morbidity in brain tumor resection? A systematic review and meta-analysis of 68 observational studies. Radiology. 2021;300(2):338–349. https://doi.org/10.1148/radiol.2021204723
191.
AldawsariAM, Al-QaisiehB, BroadbentDA, BirdD, MurrayL, SpeightR.The role and potential of using quantitative MRI biomarkers for imaging guidance in brain cancer radiotherapy treatment planning: A systematic review. Phys Imaging Radiat Oncol. 2023;27:100476. https://doi.org/10.1016/j.phro.2023.100476
192.
BurkeJF, GelbDJ, QuintDJ, MorgensternLB, KerberKA.The impact of MRI on stroke management and outcomes: a systematic review. J Eval Clin Pract. 2013;19(6):987–993. https://doi.org/https://doi.org/10.1111/jep.12011
193.
HollingworthW, MedinaLS, LenkinskiRE, . A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. Am J Neuroradiol. 2006;27(7):1404–1411.
194.
MishraRK, ChavdaVK, Moscote-SalazarLR, . Systematic review and meta-analysis of studies comparing baseline D-dimer level in stroke patients with or without cancer: strength of current evidence. J Neurosci Rural Pract. 2024;15(1):16–28. https://doi.org/10.25259/jnrp_379_2023
195.
YuanB, YangT, YanT, ChengW, BuX.Relationships between D-dimer levels and stroke risk as well as adverse clinical outcomes after acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Front Neurol. 2021;12:670730. https://doi.org/10.3389/fneur.2021.670730
196.
YangJ, HeZ, LiM, HongT, OuyangT.Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: a meta-analysis. J Stroke Cerebrovasc Dis. 2023;32(8):107243. https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107243
197.
TuttolomondoA, PecoraroR, PintoA.Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Dev Ther. 2014;8:2221–2239. https://doi.org/10.2147/DDDT.S67655
198.
LambertsenKL, FinsenB, ClausenBH.Post-stroke inflammation—target or tool for therapy? Acta Neuropathol. 2019;137(5):693–714. https://doi.org/10.1007/s00401-018-1930-z
199.
DundarA, BoldMS, AgacB, KendiAT, FriedmanSN.Stroke detection with 3 different PET tracers. Radiol Case Rep. 2019;14(11):1447–1451. https://doi.org/10.1016/j.radcr.2019.09.005
200.
DebatisseJ, EkerOF, WateauO, . PET-MRI nanoparticles imaging of blood–brain barrier damage and modulation after stroke reperfusion. Brain Commun. 2020;2(2):fcaa193. https://doi.org/10.1093/braincomms/fcaa193
201.
XuY, ColeK, CollinsE, MoledinaA, MallityC, CarrierM.Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: systematic review and meta-analysis. JACC: CardioOncol. 2023;5(4):520–532. https://doi.org/10.1016/j.jaccao.2023.04.003
202.
XianY, XuH, MatsouakaR, . Analysis of prescriptions for dual antiplatelet therapy after acute ischemic stroke. JAMA Netw Open. 2022;5(7):e2224157–e2224157. https://doi.org/10.1001/jamanetworkopen.2022.24157
203.
CaoY, YueX, JiaM, WangJ.Neuroinflammation and anti-inflammatory therapy for ischemic stroke. Heliyon. 2023;9(7):e17986. https://doi.org/10.1016/j.heliyon.2023.e17986
